Furthermore, increased CD39+ tumor-resident memory cells are associated with improved recurrence-free survival in stage III melanoma patients undergoing adjuvant immunotherapy, suggesting that this subset may function as a predictive biomarker for response to anti-PD-1 therapy [173]. This evidence concerns the gene PDCD1 and neoplasm.